AGWCA
MRNA icon

Annis Gardner Whiting Capital Advisors’s Moderna MRNA Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$827K Buy
11,813
+84
+0.7% +$4.35K 0.12% 146
2026
Q1 		$596K Buy
11,729
+16
+0.1% +$746 0.1% 172
2025
Q4 		$345K Buy
11,713
+62
+0.5% +$1.68K 0.07% 231
2025
Q3 		$301K Buy
11,651
+997
+9% +$27.8K 0.06% 234
2025
Q2 		$294K Buy
10,654
+3,125
+42% +$82.3K 0.1% 173
2025
Q1 		$213K Buy
7,529
+2,088
+38% +$74.1K 0.09% 181
2024
Q4 		$226K Buy
5,441
+725
+15% +$34.7K 0.06% 196
2024
Q3 		$315K Buy
4,716
+293
+7% +$26.9K 0.09% 177
2024
Q2 		$525K Buy
4,423
+4,420
+147,333% +$559K 0.15% 123
2024
Q1 		$320 Buy
+3
New +$302 ﹤0.01% 920
2023
Q4 		– Sell
-24
Closed -$2.48K – 710
2023
Q3 		$2.48K Buy
+24
New +$2.68K ﹤0.01% 598

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's MRNA Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors increased its Moderna (MRNA) stake by 0.72% in Q2 2026, buying an estimated $4.35K and bringing the position to 11,813 shares worth $827K. The position accounts for 0.12% of the portfolio, ranked #146.

Annis Gardner Whiting Capital Advisors first reported a position in MRNA in Q3 2023 and has held it in 11 quarters since. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors held 11,813 shares of Moderna worth $827K as of Q2 2026.
  • Annis Gardner Whiting Capital Advisors bought 84 Moderna shares in Q2 2026, an estimated $4.35K.
  • Moderna made up 0.12% of Annis Gardner Whiting Capital Advisors's portfolio in Q2 2026, its #146 holding.
  • Annis Gardner Whiting Capital Advisors first reported a position in Moderna in Q3 2023 and has held it in 11 quarters since.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.